ATE485838T1 - Oligo- oder polyalkylenglycolgekoppelte thrombininhibitoren - Google Patents
Oligo- oder polyalkylenglycolgekoppelte thrombininhibitorenInfo
- Publication number
- ATE485838T1 ATE485838T1 AT02708308T AT02708308T ATE485838T1 AT E485838 T1 ATE485838 T1 AT E485838T1 AT 02708308 T AT02708308 T AT 02708308T AT 02708308 T AT02708308 T AT 02708308T AT E485838 T1 ATE485838 T1 AT E485838T1
- Authority
- AT
- Austria
- Prior art keywords
- polyalkylene glycol
- oligo
- thrombin inhibitors
- inhibitors
- coupled
- Prior art date
Links
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 229920001515 polyalkylene glycol Polymers 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000012622 synthetic inhibitor Substances 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polyethers (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10102878A DE10102878A1 (de) | 2001-01-23 | 2001-01-23 | Oligo- oder Polyalkylengekoppelte Thrombininhibitoren |
| PCT/EP2002/000652 WO2002059065A2 (de) | 2001-01-23 | 2002-01-23 | Oligo- oder polyalkylenglycolgekoppelte thrombininhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE485838T1 true ATE485838T1 (de) | 2010-11-15 |
Family
ID=7671444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02708308T ATE485838T1 (de) | 2001-01-23 | 2002-01-23 | Oligo- oder polyalkylenglycolgekoppelte thrombininhibitoren |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7407982B2 (enExample) |
| EP (1) | EP1355674B1 (enExample) |
| JP (1) | JP4461217B2 (enExample) |
| AT (1) | ATE485838T1 (enExample) |
| CA (1) | CA2431487C (enExample) |
| DE (2) | DE10102878A1 (enExample) |
| WO (1) | WO2002059065A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10162521A1 (de) * | 2001-12-19 | 2003-07-17 | Goetz Nowak | Verwendung von molekulargewichtserweiterten Substanzen in der Tumortherapie |
| US7838560B2 (en) * | 2002-03-11 | 2010-11-23 | The Medicines Company (Leipzig) Gmbh | Urokinase inhibitors, production and use thereof |
| DE10301300B4 (de) * | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| DE10342108A1 (de) * | 2003-09-11 | 2005-04-14 | Curacyte Chemistry Gmbh | Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung |
| WO2006045503A1 (en) | 2004-10-19 | 2006-05-04 | Lonza Ag | Method for solid phase peptide synthesis |
| DE102005044319A1 (de) * | 2005-09-16 | 2007-03-22 | Curacyte Chemistry Gmbh | 2-(Aminomethyl)-5-Chlor-Benzylamid-Derivate und ihre Verwendung als Hemmstoffe des Gerinnungsfaktors Xa |
| DE102006048300A1 (de) | 2006-01-26 | 2007-08-02 | Hellstern, Peter, Prof. Dr.med. | Inhibitoren des Blutgerinnungsfaktors Xa zur Verwendung als Antikoagulans |
| WO2008032758A1 (fr) | 2006-09-15 | 2008-03-20 | Toray Industries, Inc. | Substrat et procédé pour la production de celui-ci |
| WO2008032400A1 (fr) * | 2006-09-15 | 2008-03-20 | Toray Industries, Inc. | Procédé pour la production d'un substrat modifié |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| DE102007033787A1 (de) | 2007-07-09 | 2009-01-15 | Aesculap Ag | Gefäßprothese mit reduzierter Thrombogenität |
| WO2010033226A1 (en) * | 2008-09-17 | 2010-03-25 | Nektar Therapeutics | Oligomer-protease inhibitor conjugates |
| US8835710B2 (en) * | 2009-03-24 | 2014-09-16 | Mead Johnson Nutrition Company | Animal model for infant pathologies |
| EP2518100B1 (en) | 2009-12-24 | 2015-02-18 | Toray Industries, Inc. | Hydrophilic polymer compound having anticoagulation effect |
| EP3002008B8 (en) | 2010-03-11 | 2018-10-24 | New York University | Amido compounds as roryt modulators and uses thereof |
| EP2655399B1 (en) * | 2010-12-21 | 2017-09-27 | The Medicines Company (Leipzig) GmbH | Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa |
| TW201309354A (zh) | 2011-06-23 | 2013-03-01 | Toray Industries | 醫療材料 |
| TW201311774A (zh) * | 2011-06-23 | 2013-03-16 | Toray Industries | 具有抗血液凝固作用的疏水性高分子化合物 |
| KR20140023286A (ko) * | 2011-06-24 | 2014-02-26 | 칸지 이노우에 | 유리 혈전 포획 기구 |
| RU2015148536A (ru) * | 2013-04-12 | 2017-05-18 | Торэй Индастриз, Инк. | Антитромботический искусственный кровеносный сосуд |
| EP3075400A4 (en) * | 2013-11-28 | 2017-07-19 | Toray Industries, Inc. | Anti-thrombotic material |
| BR112016018452A2 (pt) | 2014-02-12 | 2018-06-26 | Toray Industries | vaso sanguíneo artificial. |
| EP3533914B1 (en) | 2016-10-07 | 2023-03-15 | Toray Industries, Inc. | Tubular fabric |
| US12053366B2 (en) | 2017-03-31 | 2024-08-06 | Toray Industries, Inc. | Cylindrical structure |
| CN117497842B (zh) * | 2023-12-27 | 2024-03-12 | 江苏蓝固新能源科技有限公司 | 一种聚合物电解质和制备方法及其在二次电池中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010205D1 (de) * | 1989-12-01 | 1996-04-18 | Basf Ag | Hirudin-Muteine und deren Polyalkylenglykolkonjugate |
| US5583146A (en) * | 1992-12-02 | 1996-12-10 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
| DE4342154A1 (de) * | 1993-12-10 | 1995-06-14 | Behringwerke Ag | Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien |
| US5914319A (en) * | 1995-02-27 | 1999-06-22 | Eli Lilly And Company | Antithrombotic agents |
| US5798377A (en) * | 1996-10-21 | 1998-08-25 | Merck & Co., Inc. | Thrombin inhibitors |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
-
2001
- 2001-01-23 DE DE10102878A patent/DE10102878A1/de not_active Ceased
-
2002
- 2002-01-23 JP JP2002559370A patent/JP4461217B2/ja not_active Expired - Fee Related
- 2002-01-23 AT AT02708308T patent/ATE485838T1/de active
- 2002-01-23 US US10/344,722 patent/US7407982B2/en not_active Expired - Fee Related
- 2002-01-23 CA CA2431487A patent/CA2431487C/en not_active Expired - Fee Related
- 2002-01-23 EP EP02708308A patent/EP1355674B1/de not_active Expired - Lifetime
- 2002-01-23 DE DE50214734T patent/DE50214734D1/de not_active Expired - Lifetime
- 2002-01-23 WO PCT/EP2002/000652 patent/WO2002059065A2/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002059065A3 (de) | 2002-12-12 |
| US7407982B2 (en) | 2008-08-05 |
| JP4461217B2 (ja) | 2010-05-12 |
| WO2002059065A2 (de) | 2002-08-01 |
| US20050070479A1 (en) | 2005-03-31 |
| DE50214734D1 (de) | 2010-12-09 |
| EP1355674B1 (de) | 2010-10-27 |
| CA2431487A1 (en) | 2002-08-01 |
| CA2431487C (en) | 2012-03-27 |
| EP1355674A2 (de) | 2003-10-29 |
| DE10102878A1 (de) | 2002-08-01 |
| JP2004525888A (ja) | 2004-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE485838T1 (de) | Oligo- oder polyalkylenglycolgekoppelte thrombininhibitoren | |
| SE0201980D0 (sv) | Novel compounds | |
| UA74372C2 (uk) | Інгібітори серинових протеаз, фармацевтична композиція на їх основі | |
| PT1465864E (pt) | Inibidores de factor xa e outras serina proteases envolvidos na cascata da coagulacao | |
| IL222773A0 (en) | Biaryl compounds as serine protease inhibitors pharmaceutical compostions, uses, in vitro methods and devices comprising such compounds | |
| SE0201976D0 (sv) | Novel compounds | |
| DE60023266D1 (de) | Serinprotease-inhibitoren | |
| ATE296094T1 (de) | Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen | |
| NO20035603D0 (no) | Fluorpyrrolidiner som dipeptidyl peptidase inhibitorer | |
| AR031130A1 (es) | N-acilsulfonamidas promotoras de la apoptosis | |
| ATE530643T1 (de) | Säureaktive fungale protease | |
| SE0201977D0 (sv) | Novel compounds | |
| ATE330017T1 (de) | Kallikrein gen | |
| EP1399499A4 (en) | PREVENTIVE AND THERAPEUTIC AGENT FOR SEXUALLY TRANSMITTED DISEASES-I | |
| AU2001264065A1 (en) | Serine protease inhibitors | |
| AU2001264081A1 (en) | Serine protease inhibitors | |
| WO2004113278A3 (en) | Acylsulfamide inhibitors of factor viia | |
| NO20034278L (no) | Sammensetninger og fremgangsmåter til behandling av HCV- infeksjoner | |
| SE0203712D0 (sv) | Novel compounds | |
| WO2003076391A3 (de) | Hemmstoffe der urokinase, ihre herstellung und verwendung | |
| DE50105373D1 (de) | Dipeptidische hemmstoffe für den gerinnungsfaktor xa | |
| TR200402030T4 (tr) | İkame edilen I-aminobutan-3-ol-türevleri | |
| TW200700057A (en) | Alpha ketoamide compounds as cysteine protease inhibitors | |
| SE0002045D0 (sv) | New use | |
| WO2002081665A3 (en) | Implantation serine proteinases |